Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the clinical development and ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094 ...

Triple combo therapy cut 30 pounds with just 2 lbs of lean mass lost, showing strong fat-targeting results in the midstage trial. Regeneron inks $80 million deal with Hansoh for Phase 3 obesity ...